NCT00360035View on ClinicalTrials.gov

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

February 28, 2009

Conditions
Myelofibrosis
Interventions
DRUG

Obatoclax mesylate (GX15-070MS)

60 mg q2wks

Trial Locations (7)

20007

Georgetown University Medical Center, Washington D.C.

30322

Emory University, Atlanta

33612

James A. Haley Veterans Hospital, Tampa

60637

The University of Chicago, Chicago

77030

MD Anderson Cancer Center, Houston

01655

University of Massachusetts Medical Center, Worcester

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

Gemin X
All Listed Sponsors
lead

Gemin X

INDUSTRY

NCT00360035 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia | Biotech Hunter | Biotech Hunter